Brain Axis Articles & Analysis: Older
25 news found
Bened Biomedical Co, LTD., the global leader in psychobiotics with clinical studies, has acquired its US distributor Oryx Biomedical, Inc., who is pioneering the translation of microbiome research into impactful biotherapeutics and is one of the earliest stage companies bringing the gut-brain axis category of probiotics to the market. Based in Taiwan and founded ...
Kallyope, a leading biotechnology company focused on identifying and developing therapeutics targeting the gut-brain axis, and Brightseed, creators of Forager®, a pioneering artificial intelligence platform that illuminates the connections between nature and human health, have entered a strategic research collaboration to screen plant compounds to identify ...
Kallyope, Inc., a leading biotechnology company focused on identifying and developing therapeutics involving the gut-brain axis, today announced the promotion of Shirly Pinto, Ph.D., to Chief Scientific Officer and the appointments of Jiajun Liu, Ph.D., as Vice President and Head of Biometrics and Michael Crutchlow, M.D., as Vice President and Head of ...
Sosei Group Corporation (“Sosei Heptares”; TSE: 4565), the international biopharmaceutical company, and New York City-based Kallyope, pioneers in drug discovery involving the gut-brain axis, have entered a strategic research collaboration to identify and validate novel G protein-coupled receptor (GPCR) targets with a goal of creating new drug ...
The company is a scientific leader in the biological role of the microbiome-gut-brain axis and its influence on the central nervous system. Harnessing its unique expertise in the microbiome, Axial is developing small molecule drugs with defined mechanisms of action that act on new targets to mitigate the impact of metabolites and bacteria in the gut linked to ...
Kallyope, Inc., a leading biotechnology company focused on identifying and developing therapeutics targeting the gut-brain axis, today announced the appointment of Fernando Sallés, PhD, as Chief Business Officer. ...
The presentation titled, “Gut-Brain Axis: How substances produced by the microbiome may contribute to Autism Spectrum Disorder,” will be held on Saturday, April 9 from 1:00-2:00 pm PST. ...
Kallyope, Inc., a leading biotechnology company focused on identifying and developing therapeutics involving the gut-brain axis, today announced the appointments of George Shiebler as General Counsel and Anita Kawatra as Executive Vice President, Corporate Affairs, to help steer the company as it advances its pioneering drug discovery platform, clinical trials, ...
“Since our inception six years ago, Kallyope has pioneered research on the gut-brain axis and developed a transformational drug discovery platform with speed and ingenuity. ...
The paper, “A gut-derived metabolite alters brain activity and anxiety behavior in mice,” offers new mechanistic insight into how the gut microbiome can influence complex behaviors via the gut-brain axis. ...
“As we continue to advance AB-2004 through clinical development, we are excited to share these results which continue to support our previously published scientific research and preclinical data on the role of the gut-brain axis and its impact on neurological conditions,” said Dr. ...
“In keeping with Axial’s mission to fundamentally improve the management of neurological conditions through our focus on the microbiome gut-brain axis, we are truly excited to progress the clinical development of AB-2004 with the dosing of our first subjects in this double-blinded Phase 2b study,” said A. ...
Its product portfolio has potential applicability across multiple disease areas including immuno-oncology and diseases of the gut-liver-brain axis. The new facility was designed and built by Cleanroom Construction Company. ...
” AB-2004: Novel Small Molecule Therapy with Defined Mechanism of Action AB-2004 is a first-in-class, molecular therapeutic that targets the microbiome gut-brain axis and its role in autism. AB-2004 has a unique mechanism of action that selectivity sequesters certain bacterially derived metabolites in the gut before they enter the bloodstream and reach the ...
Sarkis Mazmanian at the California Institute of Technology, whohas elucidated clear biological links implicating the gut microbiome, via the gut-brain axis, in serious neurological conditions. “Axial is focused on fundamentally changing the way we approach neurological diseases by harnessing our specialized expertise on the biological role of the ...
Kallyope Inc., a leading biotechnology company focused on identifying and pursuing novel therapeutics involving the gut-brain axis, today announced that the Board of Directors has appointed Jay Galeota as President and he will succeed Nancy Thornberry as Chief Executive Officer by October 1, 2021. ...
The company is leveraging its expertise in the microbiome-gut-brain axis and its unique “omics” approach to discover and advance novel therapies that have the potential to transform paradigms in neurology and oncology. ...
Axial Therapeutics Inc., a clinical-stage biopharmaceutical company focused on leveraging the gut-brain axis for the discovery and development of small molecule therapeutics with an initial focus on autism spectrum disorder (ASD) and Parkinson’s disease (PD), today announced the appointment of A. ...
The company is leveraging its expertise in the gut-brain axis and its unique drug development platform to advance novel therapies that have the potential to transform the treatment paradigm in neurological diseases. ...
The company is leveraging its expertise in the gut-brain axis and its unique drug development platform to advance novel therapies that have the potential to transform the treatment paradigm in neurological diseases. ...